Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34763479)

  • 1. Anorectal melanoma and gene analysis of personalized adjuvant therapy: a case report.
    Cai X; Zhu X
    Ann Palliat Med; 2021 Oct; 10(10):11216-11220. PubMed ID: 34763479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
    Adileh M; Yuval JB; Huang S; Shoushtari AN; Quezada-Diaz F; Pappou EP; Weiser MR; Garcia-Aguilar J; Smith JJ; Paty PB; Nash GM
    Dis Colon Rectum; 2021 May; 64(5):555-562. PubMed ID: 33939387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anorectal melanoma.
    Fastner S; Hieken TJ; McWilliams RR; Hyngstrom J
    J Surg Oncol; 2023 Sep; 128(4):635-644. PubMed ID: 37395165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
    Schaefer T; Satzger I; Gutzmer R
    Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary anorectal malignant melanoma: an uncommon anorectal pathology.
    Juanmartiñena Fernández JF; Fernández-Urien I; Córdoba A
    Rev Esp Enferm Dig; 2016 Sep; 108(9):604-5. PubMed ID: 27056438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anorectal Melanoma - a Histopathological Case Report and a Review of the Literature.
    Kobakova I; Stoyanov G; Popov H; Spasova-Nyagulova S; Stefanova N; Stoev L; Yanulova N
    Folia Med (Plovdiv); 2018 Dec; 60(4):641-646. PubMed ID: 31188769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary anorectal malignant melanoma: A clinical, radiology and pathology correlation.
    Bohan S; Ramli Hamid MT; Poh KS; Chow TK; Chan WY
    Malays J Pathol; 2020 Dec; 42(3):461-467. PubMed ID: 33361730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
    Olbryt M; Rajczykowski M; Widłak W
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected post-operative diagnosis of primary rectal melanoma. A case report.
    Erdas E; Calò PG; Licheri S; Pomata M
    G Chir; 2014; 35(5-6):137-9. PubMed ID: 24979106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both.
    Moozar KL; Wong CS; Couture J
    Can J Surg; 2003 Oct; 46(5):345-9. PubMed ID: 14577706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
    Itoh M; Goto A; Wakasugi H; Yoshida Y; Matsunaga Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Arimura Y; Shinomura Y
    Int J Clin Oncol; 2011 Aug; 16(4):428-34. PubMed ID: 21069551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.
    Helmke BM; Mollenhauer J; Herold-Mende C; Benner A; Thome M; Gassler N; Wahl W; Lyer S; Poustka A; Otto HF; Deichmann M
    Gastroenterology; 2004 Dec; 127(6):1815-20. PubMed ID: 15578519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
    Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
    Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
    [No Abstract]   [Full Text] [Related]  

  • 16. [Diagnosis and treatment of anorectal malignant melanoma--a report of 22 cases with literature review].
    Zhong J; Zhou JN; Xu FP; Shang JQ
    Ai Zheng; 2006 May; 25(5):619-24. PubMed ID: 16687086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Primary anorectal melanoma].
    Haddad F; Nadir S; Benkhaldoun L; Alaoui R; Cherkaoui A
    Presse Med; 2005 Jan; 34(2 Pt 1):85-8. PubMed ID: 15687974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.